Literature DB >> 33870111

Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.

Muhammed Mustafa Atcı1, Çağlayan Geredeli1, Seval Ay2, Abdullah Sakin3, Biray Ertürk4, Şaban Seçmeler1, Serdar Arıcı1, Ruhper Çekin1, Nurgül Yaşar1, Orçun Can1, Şener Cihan1, Mahmut Gümüş2.   

Abstract

OBJECTIVE: This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) .
MATERIALS AND METHODS: This study enrolled patients with invasive breast cancer who have been evaluated for BRCA1/2 mutations due to the presence of high-risk factors admitted to two tertiary referral centers in Turkey. Clinical and histopathological features were analyzed in BRCA1 mutation carriers, BRCA2 mutation carriers, and non-carriers.
RESULTS: A total of 302 patients with a mean age of 44.2±9.9 (22-82) years were included. BRCA1/2 mutation was found in 75 (24%) patients, of whom 41 (13.6%) were BRCA1 mutation carriers and 37 (12.3%) were BRCA2 mutation carriers. Moreover, 104 (34.4%) and 4 (1.3%) patients had family history of breast and ovarian carcinoma, respectively. The rates of triple negativity (56.1%), histologic grade 3 (65.9%), and lymphovascular invasion (78%) were significantly higher in BRCA1 mutation carriers than in non-carriers and BRCA2 mutation carriers. Furthermore, 87% of triple-negative BRCA1 mutation carriers had histologic grade 3 tumors compared with 38.9% in non-triple-negative BRCA1 mutation carriers, and the difference was significant.
CONCLUSION: Findings of this study showed that BRCA1-related breast cancers represent a distinct group with unique pathological features, which are usually associated with a poor prognosis. ©Copyright 2021 by Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  BRCA; Triple-negative; breast cancer; grade; lymphovascular invasion

Year:  2021        PMID: 33870111      PMCID: PMC8025729          DOI: 10.4274/ejbh.galenos.2020.6346

Source DB:  PubMed          Journal:  Eur J Breast Health


  22 in total

1.  BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

Authors:  Antonino Musolino; Maria A Bella; Beatrice Bortesi; Maria Michiara; Nadia Naldi; Paola Zanelli; Marzia Capelletti; Debora Pezzuolo; Roberta Camisa; Mario Savi; Tauro M Neri; Andrea Ardizzoni
Journal:  Breast       Date:  2007-01-25       Impact factor: 4.380

2.  HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.

Authors:  Louise A Quenneville; Kelly-Anne Phillips; Hilmi Ozcelik; Robert K Parkes; Julia A Knight; Pamela J Goodwin; Irene L Andrulis; Frances P O'Malley
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

3.  Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.

Authors:  Shahrbanoo F Noori; Alexandra Gangi; Maria E Nelson; Michael Choi; Parisa Mirzadehgan; Alison K Bonk; James Mirocha; Farin Amersi; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2014-07-22       Impact factor: 5.344

4.  Novel indications for BRCA1 screening using individual clinical and morphological features.

Authors:  F Eisinger; C Noguès; J M Guinebretière; J P Peyrat; V J Bardou; T Noguchi; P Vennin; R Sauvan; R Lidereau; D Birnbaum; J Jacquemier; H Sobol
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

5.  Lymph Node Ratio Predicts Long-Term Survival in Lymph Node-Positive Breast Cancer.

Authors:  Ayşegül Sakin; Mehmet Naci Aldemir
Journal:  Eur J Breast Health       Date:  2020-07-29

6.  Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.

Authors:  Marise R Heerma van Voss; Petra van der Groep; Jos Bart; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-04-16       Impact factor: 4.430

7.  The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.

Authors:  Wen-Feng Li; Zhen Hu; Nan-Yan Rao; Chuang-Gui Song; Bin Zhang; Ming-Zhi Cao; Feng-Xi Su; Yong-Sheng Wang; Ping-Qing He; Gen-Hong Di; Kun-Wei Shen; Jiong Wu; Jin-Song Lu; Jian-Min Luo; Xiao-Yi Liu; Jie Zhou; Lei Wang; Lin Zhao; Yan-Bing Liu; Wen-Tao Yuan; Lin Yang; Zhen-Zhou Shen; Wei Huang; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2007-09-13       Impact factor: 4.872

Review 8.  BRCA mutation genetic testing implications in the United States.

Authors:  Soley Bayraktar; Banu Arun
Journal:  Breast       Date:  2016-12-06       Impact factor: 4.380

9.  BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.

Authors:  Gulsah Cecener; Unal Egeli; Berrin Tunca; Elif Erturk; Secil Ak; Sehsuvar Gokgoz; Ismet Tasdelen; Gulcin Tezcan; Elif Demirdogen; Nuran Bayram; Nilufer Avci; Turkkan Evrensel
Journal:  Cancer Invest       Date:  2014-06-02       Impact factor: 2.176

10.  Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.

Authors:  Andrea Veronesi; Clelia de Giacomi; Maria D Magri; Davide Lombardi; Martina Zanetti; Cristina Scuderi; Riccardo Dolcetti; Alessandra Viel; Diana Crivellari; Ettore Bidoli; Mauro Boiocchi
Journal:  BMC Cancer       Date:  2005-07-04       Impact factor: 4.430

View more
  3 in total

1.  Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients.

Authors:  Yoon Ju Bang; Won Kyung Kwon; Seok Jin Nam; Seok Won Kim; Byung-Joo Chae; Se Kyung Lee; Jai Min Ryu; Jong-Won Kim; Jonghan Yu; Jeong Eon Lee
Journal:  Cancer Res Treat       Date:  2021-10-13       Impact factor: 5.036

2.  Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.

Authors:  Yosr Hamdi; Najah Mighri; Maroua Boujemaa; Nesrine Mejri; Sonia Ben Nasr; Mariem Ben Rekaya; Olfa Messaoud; Hanen Bouaziz; Yosra Berrazega; Haifa Rachdi; Olfa Jaidane; Nouha Daoud; Aref Zribi; Jihene Ayari; Houda El Benna; Soumaya Labidi; Jamel Ben Hassouna; Abderazzek Haddaoui; Khaled Rahal; Farouk Benna; Ridha Mrad; Slim Ben Ahmed; Hamouda Boussen; Samir Boubaker; Sonia Abdelhak
Journal:  Front Oncol       Date:  2021-08-20       Impact factor: 6.244

Review 3.  Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.

Authors:  Xiao Luo; Qi Zhang; Hongbo Chen; Kai Hou; Ning Zeng; Yiping Wu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.